Mounjaro 7.5mg Injection contains Tirzepatide, a once-weekly injectable medicine used for the management of type 2 diabetes. It belongs to a class of medicines known as dual GIP and GLP-1 receptor agonists, which help lower blood sugar levels by improving insulin production, reducing appetite, and slowing digestion. Mounjaro is also being widely used for weight management in overweight and obese individuals under medical supervision.
Uses:
Improves blood sugar control in adults with type 2 diabetes mellitus.
Supports weight loss and management of obesity.
May be prescribed alone or in combination with other antidiabetic medicines (like metformin, insulin).
Helps reduce risk of cardiovascular complications in diabetic patients.
Dosage:
Administered once weekly via subcutaneous injection (under the skin).
Recommended dose: 7.5mg once weekly, injected into the abdomen, thigh, or upper arm.
Dosage is gradually increased based on patient tolerance and doctor’s advice.
Side Effects:
Nausea, vomiting, diarrhea, decreased appetite.
Abdominal discomfort, constipation.
Rare but serious: pancreatitis, allergic reaction, thyroid tumors (in animal studies).
Precautions:
Not for use in type 1 diabetes or diabetic ketoacidosis.
Avoid use in patients with a history of medullary thyroid carcinoma or MEN2 syndrome.
Use under strict medical supervision; regular blood sugar monitoring is required.
Not recommended during pregnancy or breastfeeding.
